Edesa Biotech Kiemelkedően
Mi az Edesa Biotech Kiemelkedően?
A Kiemelkedően az Edesa Biotech, Inc. - 18.154M
Mi a Kiemelkedően meghatározása?
A fennálló részvények egy olyan vállalat vagy pénzügyi eszköz részvényei, amelyeket a befektetők engedélyeztek, bocsátottak ki és vásároltak meg.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Kiemelkedően a Health Care szektor a NASDAQ-on cégekben a Edesa Biotech -hoz képest
Mit csinál Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
kiemelkedően -hoz hasonló cégek Edesa Biotech
- Zhongchao nak Kiemelkedően 18.103M van
- New Destiny Mining nak Kiemelkedően 18.106M van
- Gulfport nak Kiemelkedően 18.107M van
- Aptose Biosciences Inc nak Kiemelkedően 18.109M van
- Vigil Health Solutions nak Kiemelkedően 18.128M van
- Orca nak Kiemelkedően 18.151M van
- Edesa Biotech nak Kiemelkedően 18.154M van
- New Home Inc nak Kiemelkedően 18.161M van
- Career Point nak Kiemelkedően 18.163M van
- Phio Pharmaceuticals nak Kiemelkedően 18.164M van
- Vasta Platform nak Kiemelkedően 18.169M van
- Cosmo Films nak Kiemelkedően 18.173M van
- V-Mart Retail nak Kiemelkedően 18.174M van